Europe Point-of-Care Molecular Diagnostics Market To Reach $2.17 Billion By 2030

Europe Point-of-Care Molecular Diagnostics Market Growth & Trends

The Europe point-of-care molecular diagnostics market size is anticipated to reach USD 2.17 billion by 2030 and is expected to grow at a CAGR of 7.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market growth is primarily driven by the rising prevalence of infectious diseases & chronic disorders, and the growing demand for rapid test results to ensure enhanced patient outcomes.

In recent years, Europe has experienced multiple outbreaks of infectious diseases, such as vector-borne diseases like West Nile virus (WNV) and dengue fever. This has developed a demand for effective technologies, such as point-of-care molecular diagnostics, to ensure seamless operations in burdened healthcare facilities and clinics. Utilization of point-of-care molecular diagnostics has provided benefits such as quick test results, improved accuracy, reduced costs, and enhanced management of operations in the healthcare sector.

Innovation, inclusion of modern technologies, and availability through over-the-counter product ranges have driven the growth of this market. Utilization of in-home care for patients, a wide range of technology capabilities, and ease of accessibility are expected to drive the market growth during the forecast period. The use of PoC molecular diagnostics in identifying specific mutations during cancer tests is projected to add growth opportunities.

 Request a free sample copy or view report summary: Europe Point-Of-Care Molecular Diagnostics Market Report

Europe Point-of-Care Molecular Diagnostics Market Report Highlights

• Based on application, infectious diseases dominated with more than 60.0% revenue share in 2024. This is owing to the growing prevalence of communicable diseases in Europe, novel PoC solutions, and increasing use by healthcare professionals for rapid results.

• The oncology segment is expected to grow at the fastest CAGR in the European point-of-care molecular diagnostics market over the forecast period.

• Based on test location, the POC technology segment held the largest revenue share of 93.4%, in 2024. The OTC segment is expected to witness the fastest CAGR during the forecast period.

• Based on technology, PCR-based point-of-care molecular diagnostics dominated the European market with a revenue share of 67.3% in 2024. A genetic sequencing-based segment is anticipated to witness the fastest CAGR of 8.8% over the forecast period.

• Increasing research and development spending, the launch of novel solutions by key market participants, and the efficiency offered by PoC testing, especially during infectious disease outbreaks, contribute to the growth of the European point-of-care molecular diagnostics market.

Europe Point-of-Care Molecular Diagnostics Market Segmentation

Grand View Research has segmented the Europe Point of Care (PoC) molecular diagnostics market based on the application, test location, technology, end use, and country:

Europe Point-of-Care Molecular Diagnostics Application Outlook (Revenue, USD Million, 2018 - 2030)

• Infectious Diseases

  • HIV POC

  • Clostridium difficile POC

  • HBV POC

  • Pneumonia or Streptococcus associated infections

  • Respiratory syncytial virus (RSV) POC

  • HPV POC

  • Influenza/Flu POC

  • HCV POC

  • MRSA POC

  • TB and drug-resistant TB POC

  • HSV POC

  • Other Infectious Diseases

• Oncology

• Hamatology

  • Complete blood count (CBC)

  • Prothrombin time (PT)

  • Partial Thromboplastin Time (PTT)

  • Others

• Prenatal Testing

• Endocrinology

• Other Applications

Europe Point-of-Care Molecular Diagnostics Test Location Outlook (Revenue, USD Million, 2018 - 2030)

• OTC

• POC

Europe Point-of-Care Molecular Diagnostics Technology Outlook (Revenue, USD Million, 2018 - 2030)

• PCR-based

• Genetic Sequencing-based

• Hybridization-based

• Microarray-based

Europe Point-of-Care Molecular Diagnostics End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Decentralized Labs

• Hospitals

• Home-care

• Assisted Living Healthcare Facilities

• Other uses

Europe Point-of-Care Molecular Diagnostics Country Outlook (Revenue, USD Million, 2018 - 2030)

• UK

• Germany

• France

• Italy 

• Spain

• Denmark

• Sweden

• Norway

• Russia

• Netherlands

List of Key Players in the Europe point-of-care molecular diagnostics market

• Abbott

• QIAGEN

• Bayer AG

• Nova Biomedical

• Danaher

• Nipro Diagnostics (Nipro Europe Group Companies)

• Bio-Rad Laboratories, Inc

• Agilent Technologies, Inc.

• BIOMÉRIEUX

• OraSure Technologies Inc.

• Abaxis